Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection
Market price: 34,90 USD
Hikma Pharmaceuticals Plc Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||464.000.000|
|Free cash flow||240.000.000|
|Liabilities & Shareholders equity||4.135.000.000|
|Diluted shares outstanding||230.499.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||8.044.414.976,00 USD|
|Raw Data Source||IFRS in Millionen USD|
Description of the company
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.